All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.